Palisade Bio, Inc. (PALI)
NASDAQ:PALI
Want to see PALI full AI Analyst Report?
PALI Stock Chart & Stats
$2.40
-$0.36(-15.79%)
At close: 4:00 PM EST
$2.40
-$0.36(-15.79%)
Day’s Range― - ―
52-Week Range$0.53 - $2.86
Previous CloseN/A
Volume307.14K
Average Volume (3M)2.76M
Market Cap
$324.59M
Enterprise Value$172.87M
Total Cash (Recent Filing)$132.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 25, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding173,579,670
10 Day Avg. Volume2,733,782
30 Day Avg. Volume2,755,181
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$10.14Price Target Upside322.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong CapitalizationNear-zero debt and a sizable equity base provide financial flexibility to fund clinical programs and absorb R&D volatility. This durable capital structure reduces refinancing risk and supports multi-quarter trial timelines without immediate revenue dependence.
Strategic Enrollment PartnershipA formal partnership to streamline recruitment can materially shorten trial timelines and improve probability of timely data readouts. Faster enrollment reduces development risk and conserves cash, strengthening the path to clinical milestones over months.
Committed Near-term Funding From PartnerAn equity investment tied to the strategic partner both provides immediate funding for trials and aligns the partner’s incentives with clinical progress. This durable source of capital eases short-term financing pressure and supports continued R&D activity.
Bears Say
Minimal Revenue And Widening LossesPersistent lack of revenue and expanding operating losses reflect a pre-revenue clinical-stage model that will remain cash-negative until commercialization or partnering. This structural loss profile requires ongoing financing and limits internal reinvestment capacity.
Consistent Negative Operating Cash FlowSustained negative operating and free cash flow indicate ongoing cash burn from R&D. Even with some improvement, the company cannot self-fund development long-term, making it structurally dependent on external capital or milestone-based partnerships.
Authorized Share Increase Raises Dilution RiskA materially higher authorized share count provides the company with durable capacity to raise equity, but also increases the likelihood of dilution for existing holders if used to fund ongoing losses, affecting per-share economics across multiple quarters.
Palisade Bio News
PALI FAQ
What was Palisade Bio, Inc.’s price range in the past 12 months?
Palisade Bio, Inc. lowest stock price was $0.53 and its highest was $2.85 in the past 12 months.
What is Palisade Bio, Inc.’s market cap?
Palisade Bio, Inc.’s market cap is $324.59M.
When is Palisade Bio, Inc.’s upcoming earnings report date?
Palisade Bio, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 64 days.
How were Palisade Bio, Inc.’s earnings last quarter?
Palisade Bio, Inc. released its earnings results on May 12, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.043 by -$0.007.
Is Palisade Bio, Inc. overvalued?
According to Wall Street analysts Palisade Bio, Inc.’s price is currently Undervalued.
Does Palisade Bio, Inc. pay dividends?
Palisade Bio, Inc. does not currently pay dividends.
What is Palisade Bio, Inc.’s EPS estimate?
Palisade Bio, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Palisade Bio, Inc. have?
Palisade Bio, Inc. has 173,579,670 shares outstanding.
What happened to Palisade Bio, Inc.’s price movement after its last earnings report?
Palisade Bio, Inc. reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.043. Following the earnings report the stock price went down -2.604%.
Which hedge fund is a major shareholder of Palisade Bio, Inc.?
Currently, no hedge funds are holding shares in PALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.14 (322.62% Upside)
$10.14 (322.62% Upside)
Blogger Sentiment
Bullish
PALI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
192.18%
12-Months-Change
Fundamentals
Return on Equity
-36.79%
Trailing 12-Months
Asset Growth
1527.78%
Trailing 12-Months
Company Description
Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
PALI Stock 12 Month Forecast
Average Price Target
$10.14
▲(322.62% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―
Ownership Overview
2.02% Insiders
4.16% Mutual Funds
47.37% Other Institutional Investors
44.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---